196 related articles for article (PubMed ID: 8443375)
1. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
Chopra R; McMillan AK; Linch DC; Yuklea S; Taghipour G; Pearce R; Patterson KG; Goldstone AH
Blood; 1993 Mar; 81(5):1137-45. PubMed ID: 8443375
[TBL] [Abstract][Full Text] [Related]
2. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
[TBL] [Abstract][Full Text] [Related]
3. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Argiris A; Seropian S; Cooper DL
Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Girouard C; Dufresne J; Imrie K; Stewart AK; Brandwein J; Prince HM; Pantolony D; Keating A; Crump M
Ann Oncol; 1997 Jul; 8(7):675-80. PubMed ID: 9296221
[TBL] [Abstract][Full Text] [Related]
5. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
[TBL] [Abstract][Full Text] [Related]
7. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.
Chopra R; Linch DC; McMillan AK; Blair S; Patterson KG; Moir D; Richards JD; Cervi P; Kinsey S; Goldstone AH
Br J Haematol; 1992 Jun; 81(2):197-202. PubMed ID: 1643017
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[TBL] [Abstract][Full Text] [Related]
9. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
Linch DC; Winfield D; Goldstone AH; Moir D; Hancock B; McMillan A; Chopra R; Milligan D; Hudson GV
Lancet; 1993 Apr; 341(8852):1051-4. PubMed ID: 8096958
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
[TBL] [Abstract][Full Text] [Related]
11. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
[TBL] [Abstract][Full Text] [Related]
13. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
Colwill R; Crump M; Couture F; Danish R; Stewart AK; Sutton DM; Scott JG; Sutcliffe SB; Brandwein JM; Keating A
J Clin Oncol; 1995 Feb; 13(2):396-402. PubMed ID: 7844600
[TBL] [Abstract][Full Text] [Related]
14. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Schmitz N; Pfistner B; Sextro M; Sieber M; Carella AM; Haenel M; Boissevain F; Zschaber R; Müller P; Kirchner H; Lohri A; Decker S; Koch B; Hasenclever D; Goldstone AH; Diehl V; ;
Lancet; 2002 Jun; 359(9323):2065-71. PubMed ID: 12086759
[TBL] [Abstract][Full Text] [Related]
15. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
Seymour LK; Dansey RD; Bezwoda WR
Br J Cancer; 1994 Sep; 70(3):526-30. PubMed ID: 8080741
[TBL] [Abstract][Full Text] [Related]
16. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
[TBL] [Abstract][Full Text] [Related]
18. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.
Carella Am; Carlier P; Congiu A; Occhini D; Meloni G; Anselmo AP; Mandelli F; Mazza P; Tura S; Mangoni L
Leukemia; 1991; 5 Suppl 1():68-71. PubMed ID: 1890870
[TBL] [Abstract][Full Text] [Related]
19. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
Martín A; Fernández-Jiménez MC; Caballero MD; Canales MA; Pérez-Simón JA; García de Bustos J; Vázquez L; Hernández-Navarro F; San Miguel JF
Br J Haematol; 2001 Apr; 113(1):161-71. PubMed ID: 11328296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
